

Over 250 Published Studies Documenting the Validity of IVC as a Adjunctive Cancer Care Modality

- 1a - Padayatty SJ, Sun H, Wang Y, Riordan HD, Hewitt SM, Katz A, et al. Vitamin C Pharmacokinetics: Implications for Oral and Intravenous Use. *Ann Intern Med.* 2004;140:533-537. doi: 10.7326/0003-4819-140-7-200404060-00010 <https://www.ncbi.nlm.nih.gov/pubmed/15068981>
- 1b - Uetaki M, Tabata S, Nakasuka F, Soga T, Tomita M. Metabolomic alterations in human cancer cells by vitamin C-induced oxidative stress. *Scientific Reports.* 2015;5:13896. doi:10.1038/srep13896. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4563566>
- 1c - Catriona R Mayland Michael I Bennett Keith Allan, *Palliative Medicine* Vol 19, Issue 1, pp. 17 - 20 July-01-2016 10.1191/0269216305pm970oa <https://www.ncbi.nlm.nih.gov/pubmed/15690864>
- 1d - Behera M, Owonikoko TK, Chen Z, et al. Single agent maintenance therapy for advanced stage non-small cell lung cancer: A meta-analysis. *Lung Cancer (Amsterdam, Netherlands).* 2012;77(2):331-338. doi:10.1016/j.lungcan.2012.03.019. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3396772>
- 1e - Greenberg D, Earle C, Fang C-H, Eldar-Lissai A, Neumann PJ. When is Cancer Care Cost-Effective? A Systematic Overview of Cost-Utility Analyses in Oncology. *JNCI Journal of the National Cancer Institute.* 2010;102(2):82-88. doi:10.1093/jnci/djp472. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808348>
- 1f - Tengs, Tammy O.; Cost-Effectiveness versus Cost-Utility Analysis of Interventions for Cancer: Does Adjusting for Health-Related Quality of Life Really Matter? *Value in Health*, Volume 7, Issue 1, 70 - 78 <https://www.ncbi.nlm.nih.gov/pubmed/14720132>
- 1g - Padayatty SJ, Sun AY, Chen Q, Espey MG, Drisko J, Levine M. Vitamin C: Intravenous Use by Complementary and Alternative Medicine Practitioners and Adverse Effects. Gagnier JJ, ed. *PLoS ONE.* 2010;5(7):e11414. doi:10.1371/journal.pone.0011414. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2898816>
- 1h - Cancer Prevalence: How Many People Have Cancer? <http://www.cancer.org/cancer/cancerbasics/cancer-prevalence>
- =
- 1i - Padayatty SJ, Sun AY, Chen Q, Espey MG, Drisko J, Levine M. Vitamin C: Intravenous Use by Complementary and Alternative Medicine Practitioners and Adverse Effects. *PLoS ONE.* <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2898816/>. Published 2010. Accessed October 26, 2017. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2898816/>
- 1j - Christopher M. Stephenson, Robert D. Levin, [...], and Christopher G. Lis, Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer; *Cancer Chemother Pharmacol.* 2013 Jul; 72(1): 139–146. Published online 2013 May 14. doi: 10.1007/s00280-013-2179-9 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3691494>
- 1k - Malignant Metaphor, Alanna Mitchell, pg 119
- 1l - Frei B, England L, Ames BN. Ascorbate is an outstanding antioxidant in human blood plasma. *Proc Natl Acad Sci U S A.* 1989; 86(16):6377–6381. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC297842/>
- 2a - MacDonald N, Comment on "Best Supportive Care" *Cancer Prev Control.* 1998 Aug;2(4):191-2. <https://www.ncbi.nlm.nih.gov/pubmed/10093632>
- 2b - Cullen M, Comment on "'Best supportive care' has had its day." *Lancet Oncol.* 2001 Mar;2(3):173-5. <https://www.ncbi.nlm.nih.gov/pubmed/11902569>
- 2c - Ahmed N1, Ahmedzai S, Vora V, Hillam S, Paz S.; Supportive care for patients with gastrointestinal cancer.; *Cochrane Database Syst Rev.* 2004;(3):CD003445. <https://www.ncbi.nlm.nih.gov/pubmed/15266485>
- 2d - Zafar SY, Currow D, Abernethy AP.; Comments "Defining best supportive care." *J Clin Oncol.* 2008 Nov 1;26(31):5139-40. doi: 10.1200/JCO.2008.19.7491. Epub 2008 Oct 6. <https://www.ncbi.nlm.nih.gov/pubmed/18838696>
- 2e - Cherny NI1, Abernethy AP, Strasser F, Sapir R, Currow D, Zafar SY.; Improving the methodologic and ethical validity of best supportive care studies in oncology: lessons from a systematic review.; *J Clin Oncol.* 2009 Nov 10;27(32):5476-86. doi: 10.1200/JCO.2009.21.9592. Epub 2009 Jun 29.; <https://www.ncbi.nlm.nih.gov/pubmed/19564538>

- 2f - Connor SR1, Pyenson B, Fitch K, Spence C, Iwasaki K.; Comparing hospice and nonhospice patient survival among patients who die within a three-year window.; J Pain Symptom Manage. 2007 Mar;33(3):238-46.
<https://www.ncbi.nlm.nih.gov/pubmed/17349493>
- 2g - Spoelstra SL1, Given BA, Given CW, Grant M, Sikorskii A, You M, Decker V.; An intervention to improve adherence and management of symptoms for patients prescribed oral chemotherapy agents: an exploratory study. Cancer Nurs. 2013 Jan-Feb;36(1):18-28. doi: 10.1097/NCC.0b013e3182551587.
<https://www.ncbi.nlm.nih.gov/pubmed/23235499>
- 2i - Vollbracht C1, Schneider B, Leendert V, Weiss G, Auerbach L, Beuth J.; Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: results of a retrospective, multicentre, epidemiological cohort study in Germany. In Vivo. 2011 Nov-Dec;25(6):983-90.
<https://www.ncbi.nlm.nih.gov/pubmed/22021693>
- 2j - Chang Hwan Yeom, Gyou Chul Jung, and Keun Jeong Song. Changes of Terminal Cancer Patients' Health-related Quality of Life after High Dose Vitamin C Administration, J Korean Med Sci. 2007 Feb; 22(1): 7–11. Published online 2007 Feb 28. doi: 10.3346/jkms.2007.22.1.7
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2693571>
- 2k - Du WD, Yuan ZR, Sun J, Tang JX, Cheng AQ, Shen DM, Huang CJ, Song XH, Yu XF, Zheng SB; Therapeutic efficacy of high dose vitamin C on acute pancreatitis and its potential mechanisms; World J Gastroenterol. 2003 Nov;9(11):2565-9. <http://www.ncbi.nlm.nih.gov/pubmed/14606098> <http://www.wjgnet.com/10079327/full/v9/i11/2565.htm>
- 2l - Hidenori Takahashiemail, Haruyoshi Mizunoemail, Atsuo Yanagisawa High dose intravenous vitamin C improves quality of life in cancer patients; Personalized Medicine Universe 1 (2012) 49-53
[http://www.personalizedmedicineuniverse.com/article/S2186-4950\(12\)00013-2/fulltext](http://www.personalizedmedicineuniverse.com/article/S2186-4950(12)00013-2/fulltext)
- 2m - L.J.Hoffer, M.Levine, S.Assouline, D.Melnychuk, S.J.Padayatty, K.Rosadiuk, C.Rousseau, L.Robitaille & W.H.Miller Jr; Phase I clinical trial of i.v. ascorbic acid in advanced malignancy; Annals of Oncology, October 2008
<http://www.ncbi.nlm.nih.gov/pubmed/18544557> <http://annonc.oxfordjournals.org/content/19/11/1969.long>
- 2n - Ma Y, Chapman J, Levine M, Polireddy K, Drisko J, Chen Q.; High dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy;
 Sci Transl Med 5 February 2014: Vol. 6, Issue 222, p. 222
<http://www.ncbi.nlm.nih.gov/pubmed/24500406> http://medicalxpress.com/news/2014_02_intravenous_vitamin_boost_chemo_cancer_fighting.html
- 2o - Anitra C. Carr, Margreet C. M. Vissers, and John S. Cook; The Effect of Intravenous Vitamin C on Cancer and Chemotherapy Related Fatigue and Quality of Life; Front Oncol. 2014; 4: 283.
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199254>
- 2p - www.doctoryourself.com/riordan1.html
- 2q - <http://www.doctoryourself.com/RiordanIVC.pdf>
- 2s - Günes-Bayir A1, Kiziltan HS.; Palliative Vitamin C Application in Patients with Radiotherapy-Resistant Bone Metastases: A Retrospective Study.; Nutr Cancer. 2015;67(6):921-5. doi: 10.1080/01635581.2015.1055366. Epub 2015 Jul 13. <https://www.ncbi.nlm.nih.gov/pubmed/26168394>
- 2t - Jeon Y1, Park JS2, Moon S3, Yeo J4. Effect of Intravenous High Dose Vitamin C on Postoperative Pain and Morphine Use after Laparoscopic Colectomy: A Randomized Controlled Trial.; Pain Res Manag. 2016;2016:9147279. Epub 2016 Oct 30
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5107231>
- 2u - Abram Hoffer, M.D., Ph.D " Clinical Procedures in Treating Terminally Ill Cancer Patients with Vitamin C" Journal of Orthomolecular Medicine, Volume 6, Numbers 3&4, 1991, pp. 155-160
https://www.seanet.com/~alexs/ascorbate/199x/hoffer-a-j_orthomol_med-1991-v6-n3_4-p155.htm
- 2v - page xii of Cancer and Vitamin C: A Discussion of the Nature, Causes, Prevention, and Treatment of Cancer, L.P., Cameron (1993) <http://books.google.com/books?id=GSxWivFqggC&pg=PA83>
- 3a - Alexander J. Michels and Balz Frei; Myths, Artifacts, and Fatal Flaws: Identifying Limitations and Opportunities in Vitamin C Research; Nutrients. 2013 Dec; 5(12):

5161–5192. Published online 2013 Dec 16. doi: 10.3390/nu5125161 PMID: PMC3875932

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875932>

3b - L. John Hoffer, Line Robitaille, [...], and Wilson H. Miller, Jr.; High-Dose Intravenous Vitamin C Combined with Cytotoxic Chemotherapy in Patients with Advanced Cancer: A

Phase I-II Clinical Trial; PLoS One. 2015; 10(4): e0120228.; Published online 2015 Apr 7.

doi:10.1371/journal.pone.0120228; PMID: PMC4388666 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4388666>

3.3a - Thomas E Ichim, Boris Minev, ... James Koropatnick, Chien-Shing Chen and Neil H Riordan; Intravenous ascorbic acid to prevent and treat cancer-associated sepsis? Journal of Translational Medicine 2011;9:25DOI:

10.1186/1479-5876-9-25 <http://www.translational-medicine.com/content/9/1/25>

3.3b - Alpha A Fowler, III, Aamer A Syed, [...], and Ramesh Natarajan; Phase I safety trial of intravenous ascorbic acid in patients with severe sepsis; J Transl Med. 2014; 12:

32. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3937164>

3.3c - Jahan K, Ahmad K, Ali MA., Effect of ascorbic acid in the treatment of tetanus.; Bangladesh Med Res Counc Bull. 1984 Jun;10(1):24-8.; <https://www.ncbi.nlm.nih.gov/pubmed/6466264>

3.3d - Wilson JX. Mechanism of action of vitamin C in sepsis: Ascorbate modulates redox signaling in endothelium.

Biofactors. 2009 Jan–Feb; 35(1): 5–13. doi:10.1002/biof.7. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767105/>

3.3e - IVC recommended (along with thiamine and hydrocortisone) by award winning professor & MD for sepsis -

<https://www.ncbi.nlm.nih.gov/pubmed/27940189>

3.3f – Liu V, Escobar G, Greene J, et al. Hospital Deaths in Patients With Sepsis From 2 Independent Cohorts.

JAMA. 2014;312(1):90-92. <http://jama.jamanetwork.com/article.aspx?articleid=1873131&resultClick=3>

3.3g - Wheeler D, Jeffries H, Zimmerman J, Wong H, Carcillo J. Sepsis in the Pediatric Cardiac Intensive Care Unit. World J Pediatr Congenit Heart Surg. 2011;2(3):393–399.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3277844/>

3.3h – LaRosa S. Sepsis. The Cleveland Clinic Foundation. 2010.

<http://www.clevelandclinimed.com/medicalpubs/diseasemanagement/infectious-disease/sepsis/>

3.3i – Torio CM, Andrews RM. National Inpatient Hospital Costs: The Most Expensive Conditions by Payer. Agency for Healthcare Research and Quality (US). 2011.

<https://www.ncbi.nlm.nih.gov/pubmed/24199255>

3.3j – Torio C, Moore B. National Inpatient Hospital Costs: The Most Expensive Conditions b Payer, 2013. Agency for Healthcare Research and Quality. 2016.

<http://www.hcup-us.ahrq.gov/reports/statbriefs/sb204-Most-Expensive-Hospital-Conditions.pdf>

3.3k – Letarte J, Longo CJ , Pelletier J , et al. Patient characteristics and costs of severe sepsis and septic shock in Quebec. J Crit Care. 2002;17(1):39-49.

<https://www.ncbi.nlm.nih.gov/pubmed/12040548>

3.3l – Martin G. Sepsis, severe sepsis and septic shock: changes in incidence, pathogens and outcomes. [Expert Rev](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488423/)

[Anti Infect Ther. 2012; 10\(6\):701–706.](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488423/)

3.3m – Zabet M, Mohammadi M, Ramezani M. Effect of high-dose Ascorbic acid on vasopressor's requirement in septic shock. [J Res Pharm Pract](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843590/) . 2016;5(2):94–100. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843590/>

3.3n – Wilson JX , Wu F . Vitamin C in sepsis. Subcell Biochem. 2012;56:67-83. doi:

10.1007/978-94-007-2199-9_5. <https://www.ncbi.nlm.nih.gov/pubmed/22116695>

3.3o – Fisher BJ, Kraskauskas D, Martin EJ, et al. Attenuation of sepsis-induced organ injury in mice by vitamin C. [JPEN J](https://www.ncbi.nlm.nih.gov/pubmed/23917525/)

[Parenter Enteral Nutr.](https://www.ncbi.nlm.nih.gov/pubmed/23917525/) 2014;38(7):825-39. doi:

10.1177/0148607113497760. <https://www.ncbi.nlm.nih.gov/pubmed/23917525>

3.3p – Fisher BJ, Seropian IM, Kraskauskas D, et al. Ascorbic acid attenuates lipopolysaccharide-induced acute lung injury.

[Crit Care Med.](https://www.ncbi.nlm.nih.gov/pubmed/21358394/) 2011;39(6):1454-60. doi:

10.1097/CCM. <https://www.ncbi.nlm.nih.gov/pubmed/21358394>

- 3.3q - Zhou G, Kamenos G, Pendem S, et al. Ascorbate protects against vascular leakage in cecal ligation and puncture-induced septic peritonitis. *Am J Physiol Regul Integr Comp Physiol*. 2012;302(4):R409-16. doi: 10.1152/ajpregu.00153.2011. <https://www.ncbi.nlm.nih.gov/pubmed/22116513>
- 3.3r - Murata A, Morishige F, Yamaguchi H; Prolongation of survival times of terminal cancer patients by administration of large doses of ascorbate. *Int J Vitam Nutr Res Suppl*. 1982;23:103-13 <https://www.ncbi.nlm.nih.gov/pubmed/6811475>
- 3.4a - S Murad, D Grove, K A Lindberg, G Reynolds, A Sivarajah, and S R Pinnell; Regulation of collagen synthesis by ascorbic acid; May 1, 1981 vol. 78 no. 5 <http://www.pnas.org/content/78/5/2879>
- 3.4b - McCormick WJ.; Cancer: a collagen disease, secondary to a nutritional deficiency.; *Arch Pediatr*. 1959 Apr;76(4):166-71.; <https://www.ncbi.nlm.nih.gov/pubmed/13638066>
- 3.4c - Nathens AB, Neff MJ, Jurkovich GJ, et al. Randomized, prospective trial of antioxidant supplementation in critically ill surgical patients. *Ann Surg*. 2002;236(6):814-22. <https://www.ncbi.nlm.nih.gov/pubmed/12454520>
- 3.4d - Tanaka H, Matsuda T, Miyagantani Y, et al. Reduction of resuscitation fluid volumes in severely burned patients using ascorbic acid administration: a randomized, prospective study. *Arch Surg*. 2000;135(3):326-31. <https://www.ncbi.nlm.nih.gov/pubmed/10722036>
- 3.5a - Cameron E, Pauling L, Leibovitz B.; Ascorbic acid and cancer: a review.; *Cancer Res*. 1979 Mar;39(3):663-81. <https://www.ncbi.nlm.nih.gov/pubmed/371790>
- 3.6a - Park CH1, Kimler BF, Yi SY, Park SH, Kim K, Jung CW, Kim SH, Lee ER, Rha M, Kim S, Park MH, Lee SJ, Park HK, Lee MH, Yoon SS, Min YH, Kim BS, Kim JA, Kim WS.; Depletion of L-ascorbic acid alternating with its supplementation in the treatment of patients with acute myeloid leukemia or myelodysplastic syndromes.; *Eur J Haematol*. 2009 Aug;83(2):108-18. doi: 10.1111/j.1600-0609.2009.01252.x. Epub 2009 Mar 5. <https://www.ncbi.nlm.nih.gov/pubmed/19284416>
- 3.6b – Fain O, Mathieu E, Thomas M. Scurvy in patients with cancer. *BMJ*. 1998;316(7145):1661–1662. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1113239/>
- 3.7a - Nina Mikirova, Joseph Casciari, [...], and Ronald Hunninghake; Clinical experience with intravenous administration of ascorbic acid: achievable levels in blood for different states of inflammation and disease in cancer patients; *J Transl Med*. 2013; 11: 191. Published online 2013 Aug 15. doi: 10.1186/1479-5876-11-191 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751545>
- 3.7b - Vajihe Biniiaz, Mehdi Sadeghi Shermeh, [...], and Behzad Einollahi; Effect of Vitamin C Supplementation on C-reactive Protein Levels in Patients Undergoing Hemodialysis: A Randomized, Double Blind, Placebo-Controlled Study; *Nephrourol Mon*. 2014 Jan; 6(1): e13351. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3968960>
- 3.7c - Nina Mikirova, Joseph Casciari, [...], and Paul Taylor; Effect of high-dose intravenous vitamin C on inflammation in cancer patients; *J Transl Med*. 2012; 10: 189. doi: 10.1186/1479-5876-10-189 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3480897>
- 3.7d - N. Mikirova* , A. Rogers, J. Casciari, P. Taylor ; Effect of high dose intravenous ascorbic acid on the level of inflammation in patients with rheumatoid arthritis; Vol.1, No.2, 26-32 (2012) *Modern Research in Inflammation* <http://dx.doi.org/10.4236/mri.2012.12004>
- 3.7e – Mikirova N, Hunninghake R. Changes in the rate of PSA progression and the level of alkaline phosphatase during high dose vitamin C treatment of patients with prostate cancer. Vol. 7, No. 7 (2017). <https://www.ffhdj.com/index.php/ffhd/article/view/360>
- 3.8a - Yeonsil Yu, Seyeon Bae, [...], and Wang Jae Lee; The Anti-tumor Activity of Vitamin C via the Increase of Fas (CD95) and MHC I Expression on Human Stomach Cancer Cell Line, SNU1; *Immune Netw*. 2011 Aug; 11(4): 210–215. doi: 10.4110/in.2011.11.4.210 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202620>
- 3.8b - Nina A. Mikirova and Ronald Hunninghake; Effect of high dose vitamin C on Epstein-Barr viral infection; *Med Sci Monit*. 2014; 20: 725–732. doi: 10.12659/MSM.890423; <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4015650>
- 3.8c - Nelson JL1, Alexander JW, Jacobs PA, Ing RD, Ogle CK.; Metabolic and immune effects of enteral ascorbic acid after burn trauma.; *Burns*. 1992 Apr;18(2):92-7.; <https://www.ncbi.nlm.nih.gov/pubmed/1590939>

- 3.8d - Kodama M1, Kodama T, Murakami M, Kodama M; Vitamin C infusion treatment enhances cortisol production of the adrenal via the pituitary ACTH route.; *In Vivo*. 1994 Nov-Dec;8(6):1079-85.; <https://www.ncbi.nlm.nih.gov/pubmed/7772741>__
- 3.8e - Sung Hye Byun, MD and Younghoon Jeon, MD; Administration of Vitamin C in a Patient with Herpes Zoster - A case report -; *Korean J Pain*. 2011 Jun; 24(2): 108–111. doi: 10.3344/kjp.2011.24.2.108; <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3111558>__
- 3.8f - Kodama M1, Oyama A, Takagi H.; Control of interstitial pneumonia by drip infusion of megadose vitamin C, dehydroepiandrosterone and cortisol. A short review of our experience.; *In Vivo*. 2008 Mar-Apr;22(2):263-7.; <https://www.ncbi.nlm.nih.gov/pubmed/18468413>__
- 3.9a - Espey MG1, Chen P, Chalmers B, Drisko J, Sun AY, Levine M, Chen Q.; Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer.; *Free Radic Biol Med*. 2011 Jun 1;50(11):1610-9. doi: 10.1016/j.freeradbiomed.2011.03.007. Epub 2011 Mar 12.; <https://www.ncbi.nlm.nih.gov/pubmed/21402145>__
- 3.9b - Verrax J1, Calderon PB.; Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects.; *Free Radic Biol Med*. 2009 Jul 1;47(1):32-40. doi: 10.1016/j.freeradbiomed.2009.02.016. Epub 2009 Feb 28.; <https://www.ncbi.nlm.nih.gov/pubmed/19254759>__
- 3.9c - Lamson DW1, Brignall MS.; Antioxidants in cancer therapy; their actions and interactions with oncologic therapies.; *Altern Med Rev*. 1999 Oct;4(5):304-29.; <https://www.ncbi.nlm.nih.gov/pubmed/10559547>
- 3.9d - Prasad KN1, Kumar A, Kochupillai V, Cole WC.; High doses of multiple antioxidant vitamins: essential ingredients in improving the efficacy of standard cancer therapy.; *J Am Coll Nutr*. 1999 Feb;18(1):13-25.; <https://www.ncbi.nlm.nih.gov/pubmed/10067654>__
- 3.9e - Prasad KN1.; Multiple dietary antioxidants enhance the efficacy of standard and experimental cancer therapies and decrease their toxicity.; *Integr Cancer Ther*. 2004 Dec;3(4):310-22.; <https://www.ncbi.nlm.nih.gov/pubmed/15523102>__
- 3.9f - Simone CB 2nd1, Simone NL, Simone V, Simone CB.; Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill and increase survival, part 1.; *Altern Ther Health Med*. 2007 Jan-Feb;13(1):22-8.; <https://www.ncbi.nlm.nih.gov/pubmed/17283738>__
- 3.9g - Simone CB 2nd1, Simone NL, Simone V, Simone CB.; Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill and increase survival, Part 2.; *Altern Ther Health Med*. 2007 Mar-Apr;13(2):40-7.; <https://www.ncbi.nlm.nih.gov/pubmed/17405678>__
- 3.9h - Daniel A. Monti, Edith Mitchell, [...], and Mark Levine; Phase I Evaluation of Intravenous Ascorbic Acid in Combination with Gemcitabine and Erlotinib in Patients with Metastatic Pancreatic Cancer; *PLoS One*. 2012; 7(1): e29794. doi: 10.1371/journal.pone.0029794; <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3260161/>__
- 3.9i - Block KI1, Koch AC, Mead MN, Tothy PK, Newman RA, Gyllenhaal C.; Impact of antioxidant supplementation on chemotherapeutic efficacy: a systematic review of the evidence from randomized controlled trials.; *Cancer Treat Rev*. 2007 Aug;33(5):407-18. Epub 2007 Mar 23.; <https://www.ncbi.nlm.nih.gov/pubmed/17367938>__
- 3.9j - Prasad KN1.; Rationale for using high-dose multiple dietary antioxidants as an adjunct to radiation therapy and chemotherapy.; *J Nutr*. 2004 Nov;134(11):3182S-3S.; <https://www.ncbi.nlm.nih.gov/pubmed/15514298>
- 3.9k - Joseph J. Cullen, Douglas R. Spitz, and Garry R. Buettner; Comment on “Pharmacologic ascorbate synergizes with Gemcitabine in pre-clinical models of pancreatic cancer” i.e. All we are saying is, give C a chance; *Free Radic Biol Med*. 2011 Jun 15; 50(12): 1726–1727. doi: 10.1016/j.freeradbiomed.2011.03.030; <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3128375/pdf/nihms304544.pdf>
- 3.9l - JJ Casciari, NH Riordan, TL Schmidt, XL Meng, JA Jackson, and HD Riordan; Cytotoxicity of ascorbate, lipoic acid, and other antioxidants in hollow fibre in vitro tumours; *British Journal of Cancer* (2001) 84(11), 1544–1550 doi: 10.1054/ bjoc.2001.1814.; <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363673/pdf/84-6691814a.pdf>__
- 3.9m - Michael Graham Espey, Ping Chen, [...], and Qi Chen; Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer; *Free Radic Biol Med*. 2011 Jun 1; 50(11): 1610–1619. doi: 10.1016/j.freeradbiomed.2011.03.007; <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3482496/>__
- 3.9n - Schoenfeld, Sibenaller, Mapuskar, Wagner, Cramer-Morales, Furqan, Sandhu, Carlisle, Smith, Abu Hejleh, Berg, Zhang, Keech, Parekh, Bhatia, Monga V2, Bodeker, Ahmann, Vollstedt, Brown, Shanahan Kauffman, Schall,

Hohl, Clamon, Greenlee, Howard, Shultz, Smith, Riley, Domann, Cullen, Buettner, Buatti, Spitz, Allen. O2.- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. *Cancer Cell*. 2017 Mar 16. pii: S1535-6108(17)30062-4. doi: 10.1016/j.ccell.2017.02.018 <https://www.ncbi.nlm.nih.gov/pubmed/28366679>

3.9o - Cimmino L, Dolgalev I, Wang Y et al. Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression. NYU School of Medicine. 2017;170(6):1079-1095 <https://www.ncbi.nlm.nih.gov/labs/articles/28823558/>

3.10a - Shinozaki K1, Hosokawa Y, Hazawa M, Kashiwakura I, Okumura K, Kaku T, Nakayama E.; Ascorbic acid enhances radiation-induced apoptosis in an HL60 human leukemia cell line.; *J Radiat Res*. 2011;52(2):229-37. Epub 2011 Feb 19.; <https://www.ncbi.nlm.nih.gov/pubmed/21343676>

3.10b - Herst PM1, Broadley KW, Harper JL, McConnell MJ.; Pharmacological concentrations of ascorbate radiosensitize glioblastoma multiforme primary cells by increasing oxidative DNA damage and inhibiting G2/M arrest.; *Free Radic Biol Med*. 2012 Apr 15;52(8):1486-93. doi: 10.1016/j.freeradbiomed.2012.01.021. Epub 2012 Feb 2.; <https://www.ncbi.nlm.nih.gov/pubmed/22342518>

3.10c - Castro ML1, McConnell MJ1, Herst PM2.; Radiosensitisation by pharmacological ascorbate in glioblastoma multiforme cells, human glial cells, and HUVECs depends on their antioxidant and DNA repair capabilities and is not cancer specific.; *Free Radic Biol Med*. 2014 Sep;74:200-9. doi: 10.1016/j.freeradbiomed.2014.06.022. Epub 2014 Jun 30.; <https://www.ncbi.nlm.nih.gov/pubmed/24992837>

3.11a - Nina A Mikirova,corresponding author#1 Thomas E Ichim,#2 and Neil H Riordan#2; Anti-angiogenic effect of high doses of ascorbic acid; *J Transl Med*. 2008; 6: 50. doi: 10.1186/1479-5876-6-50; <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2562367>

3.11b - Mikirova N1, Riordan N2, Casciari J3.; Modulation of Cytokines in Cancer Patients by Intravenous Ascorbate Therapy.; *Med Sci Monit*. 2016 Jan 3;22:14-25.; <https://www.ncbi.nlm.nih.gov/pubmed/26724916>

3.11c - Ashino H1, Shimamura M, Nakajima H, Dombou M, Kawanaka S, Oikawa T, Iwaguchi T, Kawashima S.; Novel function of ascorbic acid as an angiostatic factor.; *Angiogenesis*. 2003;6(4):259-69.; <https://www.ncbi.nlm.nih.gov/pubmed/15166494>

3.11d - Nina A Mikirova,corresponding author#1 Joseph J Casciari,#1 and Neil H Riordan#1; Ascorbate inhibition of angiogenesis in aortic rings ex vivo and subcutaneous Matrigel plugs in vivo; *J Angiogenes Res*. 2010; 2: 2. doi: 10.1186/2040-2384-2-2; <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2820478>

3.12a - Levine M1, Padayatty SJ, Espey MG.; Vitamin C: a concentration-function approach yields pharmacology and therapeutic discoveries.; *Adv Nutr*. 2011 Mar;2(2):78-88. doi: 10.3945/an.110.000109. Epub 2011 Mar 10.; <https://www.ncbi.nlm.nih.gov/pubmed/22332036>

3.12b - Chen Q, Espey MG, Krishna MC, et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissues. *Proceedings of the National Academy of Sciences of the United States of America*. 2005;102(38):13604-13609. doi:10.1073/pnas.0506390102. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1224653/>

3.12c - Chen Q, Espey MG, Sun AY, et al. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. *Proceedings of the National Academy of Sciences of the United States of America*. 2007;104(21):8749-8754. doi:10.1073/pnas.0702854104. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1885574/>

3.12d - Cameron E, Campbell A.; The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer.; *Chem Biol Interact*. 1974 Oct;9(4):285-315.; <https://www.ncbi.nlm.nih.gov/pubmed/4430016>

3.12e - Mastrangelo D, Massai L, Lo Coco F, Noguera NI, Borgia L, Fioritoni G, Berardi A, Iacone A, Muscettola M, Pelosi E, Castelli G, Testa U, Di Pisa F, Grasso G.; Cytotoxic effects of high concentrations of sodium ascorbate on human myeloid cell lines.; *Ann Hematol*. 2015 Nov;94(11):1807-16. doi: 10.1007/s00277-015-2464-2.; <https://www.ncbi.nlm.nih.gov/pubmed/26264692>

3.12f - Chen Q1, Espey MG, Sun AY, Pooput C, Kirk KL, Krishna MC, Khosh DB, Drisko J, Levine M.; Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice.; *Proc Natl Acad*

Sci U S A. 2008 Aug 12;105(32):11105-9. doi: 10.1073/pnas.0804226105.;
<https://www.ncbi.nlm.nih.gov/pubmed/18678913>

3.12g - Uetaki M, Tabata S, Nakasuka F, Soga T, Tomita M. Metabolomic alterations in human cancer cells by vitamin C-induced oxidative stress. *Scientific Reports*. 2015;5:13896. doi:10.1038/srep13896. <http://www.nature.com/articles/srep13896>

3c - Liu V, Escobar GJ, Greene JD, Soule J, Whippy A, Angus DC, Iwashyna TJ.; Hospital deaths in patients with sepsis from 2 independent cohorts.; *JAMA*. 2014 Jul 2;312(1):90-2.; <https://www.ncbi.nlm.nih.gov/pubmed/24838355>

=

3d - Fowler AA, Syed AA, Knowlson S, et al. Phase I safety trial of intravenous ascorbic acid in patients with severe sepsis. *Journal of Translational Medicine*. 2014;12:32. doi:10.1186/1479-5876-12-32.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3937164/>

3e1 "Chapter 17: Electron Transport and Oxidative Phosphorylation", *Biology* 638, Takusagawa
<https://drive.google.com/file/d/0B3dbrj98d4NEdFpfdXVPOEJoUDQ/view?usp=sharing>

3e2 Combs J, Gerald F. *The Vitamins*. 4 ed. Burlington: Elsevier Science; 2012) and (Erdman JW, MacDonald I, Zeisel SH, International Life Sciences Institute. *Present knowledge in nutrition*. 10th ed. Ames, Iowa: International Life Sciences Institute; 2012

3f - Astuya A, Caprile T, Castro M, Salazar K, García Mde L, Reinicke K, Rodríguez F, Vera JC, Millán C, Ulloa V, Low M, Martínez F, Nualart F.; Vitamin C uptake and recycling among normal and tumor cells from the central nervous system.; *J Neurosci Res*. 2005 Jan 1-15;79(1-2):146-56.; <https://www.ncbi.nlm.nih.gov/pubmed/15578707>

3g - Yun J, Rago C, Cheong I, et al. Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells. *Science*. 2009;325(5947):1555.
Doi:10.1126/science.1174229. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2820374/>

3h - Yun J, Mullarky E, Lu C, et al. Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. *Science*. 2015; 350(6266):1391-1396. doi:10.1126/science.aaa5004.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4778961/>

3i - Bram S, Froussard P, Guichard M, et al. Vitamin C preferential toxicity for malignant melanoma cells. *Nature*. 1980 Apr 17;284(5757):629-31. <https://www.ncbi.nlm.nih.gov/pubmed/7366735>

3j - Toohey JI. Dehydroascorbic acid as an anti-cancer agent. *Cancer Lett*. 2008;263(2):164-9. doi: 10.1016/j.canlet.2008.02.002. <https://www.ncbi.nlm.nih.gov/pubmed/18378072>

4a - Jin Ge, BSE, Jessica Fishman, PhD, Neha Vapiwala, MD, Susan Q. Li, MS, Krupali Desai, MD, MPH, Sharon X. Xie, PhD, and Jun J. Mao, MD, MSCE; Patient-Physician Communication About Complementary and Alternative Medicine in a Radiation Oncology Setting; *Int J Radiat Oncol Biol Phys*. 2013 Jan 1; 85(1): e1-e6. doi: 10.1016/j.ijrobp.2012.08.018; <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3677204/>

4b - Padayatty SJ, Sun AY, Chen Q, et al. Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. *PLoS One*. 2010;5(7):e11414. doi: 10.1371/journal.pone.0011414. <http://www.ncbi.nlm.nih.gov/pubmed/20628650>

4c - Williams MD, Braun LA, Cooper LM, et al. Hospitalized cancer patients with severe sepsis: analysis of incidence, mortality, and associated costs of care. *Crit Care*. 2004; 8(5): R291-R298. Doi:10.1186/cc2893. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1065011/>

4d - Medicine: Hydration Therapy (L34263), LCD - Local Coverage Determination, Medicare Policies and Guidelines
<https://goo.gl/isafwz>

4e - Hyperchloremia (High Chloride), What Is Hyperchloremia?
<http://chemocare.com/chemotherapy/side-effects/hyperchloremia-high-chloride.aspx>

5a - Mack JW, Smith TJ. J Reasons why physicians do not have discussions about poor prognosis, why it matters, and what can be improved. *Clin Oncol*. 2012 Aug 1;30(22):2715-7. doi: 10.1200/JCO.2012.42.4564. Epub 2012 Jul 2. PMID: 22753911- <http://www.ncbi.nlm.nih.gov/pubmed/22753911>

5b - Christakis NA, Lamont EB. Extent and determinants of error in doctors' prognoses in terminally ill patients: prospective cohort study. *BMJ*. 2000;320(7233):469-72.
<http://www.ncbi.nlm.nih.gov/pubmed/10678857>

- 5c - Lee SJ, Fairclough D, Antin JH. Discrepancies between patient and physician estimates for the success of stem cell transplantation. *JAMA*. 2001;285(8):1034-8. <http://www.ncbi.nlm.nih.gov/pubmed/11209174>
- 5d - Rees DC, Kelsey H, Richards JDM. Acute haemolysis induced by high dose ascorbic acid in glucose-6-phosphate dehydrogenase deficiency. *BMJ*. 1993;306:841-2. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1677333/pdf/bmj00013-0043.pdf>
- 5e - Hoffer LJ, Levine M, Assouline S, Melnychuk D, Padayatty SJ, Rosadiuk K, et al. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO*. 2008;19(11):1969-74. Epub 2008/06/12
- 5f - Robitaille L, Mamer OA, Miller WH Jr, et al. Oxalic acid excretion after intravenous ascorbic acid administration. *Metabolism*. 2009;58(2):263-9. doi:10.1016/j.metabol.2008.09.023. <http://www.ncbi.nlm.nih.gov/pubmed/19154961/>
- 5g - Padayatty SJ, Sun AY, Chen Q, et al. Vitamin C: Intravenous Use by Complementary and Alternative Medicine Practitioners and Adverse Effects. *PLoS One*. 2010;5(7): e11414. doi:10.1371/journal.pone.0011414. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2898816/>
- 5h - Rattan V, Sidhu H, Vaidyanathan S, et al. Effect of combined supplementation of magnesium oxide and pyridoxine in calcium-oxalate stone formers. *Urol Res*. 1994;22(3):161-5. <http://www.ncbi.nlm.nih.gov/pubmed/7992461>
- 5i - Shahrbanoo K, Taziki O. Effect of intravenous ascorbic acid in hemodialysis patients with anemia and hyperferritinemia. *Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia*. 2008;19(6):933-6. Epub 2008/11/01
- 5j - Orthomolecular Medicine News Service. What Really Causes Kidney Stones, 2013. <http://www.orthomolecular.org/resources/omns/v09n05.shtml>
- 5k - Wandzilak TR, D'Andre SD, Davis PA, et al. Effect of high dose vitamin C on urinary oxalate levels. *J Urol*. 1994;151(4):834-7. <http://www.ncbi.nlm.nih.gov/pubmed/8126804>
- 5l - Robitaille L, Mamer OA, Miller WH Jr., et al. Oxalic acid excretion after intravenous ascorbic acid administration. *Metabolism*. 2009;58(2):263-269. doi: 10.1016/j.metabol.2008.09.023 . <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3482487/>
- 5n - Curhan GC, Willett WC, Rimm EB, et al. A prospective study of the intake of vitamins C and B6, and the risk of kidney stones in men. *J Urol*. 1996 Jun;155(6):1847-51. <http://www.ncbi.nlm.nih.gov/pubmed/8618271>
- 5o - Curhan GC, Willett WC, Speizer FE, et al. Intake of vitamins B6 and C and the risk of kidney stones in women. *J Am Soc Nephrol*. 1999;10(4):840-5. <http://www.ncbi.nlm.nih.gov/pubmed/10203369>
- 5p - "the incidence of calcium oxalate stones during or following IVC is negligible" - Orthomolecular Enlightenment, Volker H. Schendel, pg 14
- 5p2 - Orthomolecular Medicine for Everyone, Abram Hoffer, Andrew Saul, pg 103
- 5p3 - Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before-After Study <https://www.ncbi.nlm.nih.gov/pubmed/27940189>
- 5q - Heaney ML, Gardner JR, Karasavvas N, et al. Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. *Cancer Res*. 2008;68(19):8031-8038. doi: 10.1158/0008-5472.CAN-08-1490. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3695824/>
- 5r - Padayatty SJ, Sun H, Wang Y, et al. Vitamin C pharmacokinetics: implications for oral and intravenous use. *Ann Intern Med*. 2004 Apr 6;140(7):533-7. <http://www.ncbi.nlm.nih.gov/pubmed/15068981>
- 5s - Levine M, Espey MG, Chen Q. Losing and finding a way at C: New promise for pharmacologic ascorbate in cancer treatment. *Free Radic Biol Med*. 2009;47(1):27-29. doi:10.1016/j.freeradbiomed.2009.04.001 . <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2981594/>
- 5t - Verrax J, Calderon PB. Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. *Free Radic Biol Med*. 2009;47(1):32-40. doi:10.1016/j. <http://www.ncbi.nlm.nih.gov/pubmed/19254759>

5u - Chen Q, Espey MG, Krishna MC, et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissues. *Proc Natl Acad Sci U S A*. 2005;102(38):13604–13609. doi: [10.1073/pnas.0506390102](https://doi.org/10.1073/pnas.0506390102) . [PMC1224653](https://pubmed.ncbi.nlm.nih.gov/1224653/)__

5v - Pecherer B. The Preparation of Dehydro-L-ascorbic Acid and its Methanol Complex. Some Reactions of Dehydro-L-ascorbic Acid. *J. Am. Chem. Soc.* . 1951;73(8):3827–3830. DOI: 10.1021/ja01152a080 <http://pubs.acs.org/doi/abs/10.1021/ja01152a080>__

5w - Levine M, Espey MG, Chen Q. Losing and finding a way at C: New promise for pharmacologic ascorbate in cancer treatment. *Free Radic Biol Med*. 2009;47(1):27-29. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2981594>

5x - Monti DA, Mitchell E, Bazzan AJ, et al. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. *PLoS One*. 2012;7(1):e29794. doi: 10.1371/journal.pone.0029794. <http://www.ncbi.nlm.nih.gov/pubmed/22272248>__

5y - see citation #10 in this web archived page: <http://web.archive.org/web/20121005091700/http://www.mskcc.org/cancer-care/herb/vitamin-c>

5z - Antioxidants: the Real Story <http://orthomolecular.org/resources/omns/v09n09.shtml>

5aa - Moertel CG, Fleming TR, Creagan ET, et al. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. *N Engl J Med*__ 1985;312(3):137-41. <http://www.ncbi.nlm.nih.gov/pubmed/3880867>__

5ab - Padayatty SJ, Sun H, Wang Y, et al. Vitamin C pharmacokinetics: implications for oral and intravenous use. *Ann Intern Med*__ 2004;140(7):533-7. <http://www.ncbi.nlm.nih.gov/pubmed/15068981>

5ac - Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: Reevaluation of prolongation of survival times in terminal human cancer. *Proc Natl Acad Sci U S A* . 1978;75(9):4538–4542. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC336151/>__

5ad - Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. *Proc Natl Acad Sci U S A* . 1976;73(10):3685–3689. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC431183__

5ae - Qi Chen Q, Espey MG, Krishna MC, et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissues. *Proc Natl Acad Sci U S A* . 2005;102(38):13604–13609. doi: 10.1073/pnas.0506390102 <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1224653/>

5af - Chen Q, Espey MG, Sun AY, et al. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. *Proc Natl Acad Sci U S A* . 2007;104(21):8749–8754. doi: 10.1073/pnas.0702854104 . <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1885574/>__

5ag -Cabanillas F. Vitamin C and cancer: what can we conclude--1,609 patients and 33 years later?. *P R Health Sci J*. 2010;29(3):215-7. <http://www.ncbi.nlm.nih.gov/pubmed/20799507>

5ag2 - https://www.academia.edu/21083299/Vitamin_C_and_cancer_what_can_we_conclude--1_609_patients_and_33_years_later_comment_on_the_article_by_Cabanillas

5ah - Parrow NL, Leshin JA, Levine M. Parenteral ascorbate as a cancer therapeutic: a reassessment based on pharmacokinetics. *Antioxid Redox Signal*. 2013;19(17):2141-56. doi: 10.1089/ars.2013.5372. <http://www.ncbi.nlm.nih.gov/pubmed/23621620>__

5ai - Carr A, Frei B. Does vitamin C act as a pro-oxidant under physiological conditions? *FASEB J*. 1999;13(9):1007-24. <http://www.ncbi.nlm.nih.gov/pubmed/10336883?dopt=Abstract>

5aj - Do websearch: "Vitamin C Doesn't Cause Cancer!, LPI" <http://lpi.oregonstate.edu/f-w01/cancer.html>__

5ak - Michels AJ, Frei B. Myths, Artifacts, and Fatal Flaws: Identifying Limitations and Opportunities in Vitamin C Research. *Nutrients* . 2013;5(12):5161–5192. doi: 10.3390/nu5125161 . <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875932/>__

5al – London North West Healthcare (NHS). Glucose 6 Phosphate Dehydrogenase (G6PD) Deficiency. <http://www.sickle-thal.nwlh.nhs.uk/blood/G6pdDeficiency.aspx>__

- 5am - Michael Traub, Paul Anderson. Intravenous Vitamin C in Cancer, A Brief Overview of it's Use and Considerations. Natural Medical Journal, Feb 2014 Vol 6 Issue 21.
<https://www.naturalmedicinejournal.com/journal/2014-02/intravenous-vitamin-c-cancer>
- 5an - <https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2014.html>
- 5ao -T. Greenhalgh. Getting your bearings (deciding what the paper is about) BMJ. 1997 Jul 26;315(7102):243-6.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2127173/pdf/9253275.pdf>
- 6a - Mikirova N, Casciari J, Riordan N, et al. Clinical experience with intravenous administration of ascorbic acid: achievable levels in blood for different states of inflammation and disease in cancer patients. J Transl Med . 2013;11:191.doi: 10.1186/1479-5876-11-191 <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751545/>
- 6b -Riordan HD, Casciari JJ, González MJ, et al. A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. P R Health Sci J. 2005;24(4):269-76.
<http://www.ncbi.nlm.nih.gov/pubmed/16570523>
- 6c - Hoffer LJ, Levine M, Assouline S, et al. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol. 2008;19(11):1969-74. doi: 10.1093/annonc/mdn377. <http://www.ncbi.nlm.nih.gov/pubmed/18544557>
- 6d - Monti DA, Mitchell E, Bazzan AJ, et al. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One. 2012;7(1):e29794. doi: 10.1371/journal.pone.0029794. <http://www.ncbi.nlm.nih.gov/pubmed/22272248>
- 6e - Stephenson CM, Levin RD, Spector T, et al. Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer. Cancer Chemother Pharmacol. 2013;72(1):139-46. doi: 10.1007/s00280-013-2179-9. <http://www.ncbi.nlm.nih.gov/pubmed/23670640>
- 6f - Padayatty SJ, Sun AY, Chen Q, et al. Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One. 2010;5(7):e11414. doi: 10.1371/journal.pone.0011414.
<http://www.ncbi.nlm.nih.gov/pubmed/20628650>
- 6g - Michels AJ, Frei B. Myths, Artifacts, and Fatal Flaws: Identifying Limitations and Opportunities in Vitamin C Research. Nutrients. 2013;5(12):5161–5192.
doi:10.3390/nu5125161. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875932>
- 6h - Riordan HD, Hunninghake RB, Riordan NH, et al. Intravenous ascorbic acid: protocol for its application and use. P R Health Sci J. 2003;22(3):287-90. <http://www.ncbi.nlm.nih.gov/pubmed/14619456>
- 6i - Monti DA, Mitchell E, Bazzan AJ, et al. Phase I Evaluation of Intravenous Ascorbic Acid in Combination with Gemcitabine and Erlotinib in Patients with Metastatic Pancreatic Cancer. PLoS One. 2012;7(1):e29794.
Doi:10.1371/journal.pone.0029794. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3260161>
- 6j - Ma Y, Sullivan GG, Schrick E, et al. A Convenient Method for Measuring Blood Ascorbate Concentrations in Patients Receiving High-Dose Intravenous Ascorbate. J Am Coll Nutr. 2013; 32(3):187–193.
doi:10.1080/07315724.2013.791167. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3725640/> 6k -
<http://orthomed.org/omt/NMH-Drisko.mp3>
- 6l – Riordan H, Riordan N, Casciari J, et al. THE RIORDAN INTRAVENOUS VITAMIN C(IVC) PROTOCOL FOR ADJUNCTIVE CANCER CARE: IVC AS A CHEMOTHERAPEUTIC AND BIOLOGICAL RESPONSEMODIFYING AGENT. Riordan Clinic IVC Protocol. https://riordanclinic.org/wp-content/uploads/2015/11/RiordanIVCprotocol_en.pdf
- 6m - Bromley J, Hughes BG, Leong DC, et al. Life-threatening interaction between complementary medicines: cyanide toxicity following ingestion of amygdalin and vitamin C. Ann Pharmacother. 2005;39(9):1566-9. <http://www.ncbi.nlm.nih.gov/pubmed/16014371>
- 6n - Cameron E, Campbell A. The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chem Biol Interact. 1974;9(4):285-315. <http://www.ncbi.nlm.nih.gov/pubmed/4430016>
- 6o - Winkler BS, Orselli SM, Rex TS. The redox couple between glutathione and ascorbic acid: a chemical and physiological perspective. Free Radic Biol Med. 1994;17(4):333-49. <http://www.ncbi.nlm.nih.gov/pubmed/8001837>

- 6p - Winterbourn CC, Metodiewa D. Reactivity of biologically important thiol compounds with superoxide and hydrogen peroxide. *Free Radic Biol Med.* 1999;27(3-4):322-8. <http://www.ncbi.nlm.nih.gov/pubmed/10468205>
- 6q - Chen P, Stone J, Sullivan G, et al. Anti-cancer effect of pharmacologic ascorbate and its interaction with supplementary parenteral glutathione in preclinical cancer models. *Free Radic Biol Med.* 2011;51(3):681-7. doi:10.1016/j. <http://www.ncbi.nlm.nih.gov/pubmed/21672627>
- 6r - Uetaki M, Tabata S, Nakasuka F, et al. Metabolomic alterations in human cancer cells by vitamin C-induced oxidative stress. *Sci Rep.* 2015;5:13896. doi:10.1038/srep13896. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4563566/>
- 6s -Perego P, Gatti L, Carenini N, et al. Apoptosis induced by extracellular glutathione is mediated by H₂O₂ production and DNA damage. *Int J Cancer.* 2000;87(3):343-8. <https://www.ncbi.nlm.nih.gov/pubmed/10897038>
- 6t - Donnerstag B, Ohlenschlager G, Cinatl J, et al. Reduced glutathione and S-acetylgutathione as selective apoptosis-inducing agents in cancer therapy. *Cancer Lett.* 1996;110(1-2):63-70. <https://www.ncbi.nlm.nih.gov/pubmed/9018082>
- 6u - Ian Dettman, Cliff Meakin, Rob Allen; Co-Infusing Glutathione and Vitamin C During Cancer Treatment; ACNEM Journal Vol31 No1 - March2012
- 6v - [http://www.nutritioncollege.org/sites/default/files/Co-infusing glutathione and vitamin C during cancer treatment - a reply.pdf](http://www.nutritioncollege.org/sites/default/files/Co-infusing%20glutathione%20and%20vitamin%20C%20during%20cancer%20treatment%20-%20a%20reply.pdf)
- 6w - Uetaki M, Tabata S, Nakasuka F, et al. Metabolomic alterations in human cancer cells by vitamin C-induced oxidative stress. *Sci Rep.* 2015;5:13896. doi:10.1038/srep13896. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4563566/>
- 6x - Michels AJ, Frei B. Myths, Artifacts, and Fatal Flaws: Identifying Limitations and Opportunities in Vitamin C Research. *Nutrients.* 2013;5(12):5161–5192.doi:10.3390/nu5125161. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875932/>
- 6y - PATTERSON JW. Course of diabetes and development of cataracts after injecting dehydroascorbic acid and related substances. *Am J Physiol.* 1951;165(1):61-5. <http://www.ncbi.nlm.nih.gov/pubmed/14829572>
- 6z - Padayatty SJ, Sun AY, Chen Q, et al. Vitamin C: Intravenous Use by Complementary and Alternative Medicine Practitioners and Adverse Effects. *PLoS One.* 2010;5(7):e11414. doi:10.1371/journal.pone.0011414. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2898816>
- 6aa - Pecherer B. The Preparation of Dehydro-L-ascorbic Acid and its Methanol Complex. Some Reactions of Dehydro-L-ascorbic Acid · *J. Am. Chem. Soc.* , 1951;73(8):3827–3830. DOI: 10.1021/ja01152a080. <http://pubs.acs.org/doi/abs/10.1021/ja01152a080>
- 6ab - Astuya A, Caprile T, Castro M, et al. Vitamin C uptake and recycling among normal and tumor cells from the central nervous system. *J Neurosci Res.* 2005;79(1-2):146-56. <http://www.ncbi.nlm.nih.gov/pubmed/15578707>
- 6ac - Cameron E, Campbell A. The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. *Chem Biol Interact.* 1974;9(4):285-315. <http://www.ncbi.nlm.nih.gov/pubmed/4430016>
- 6ad - <https://www.youtube.com/watch?v=Ibz0IHGNCCU>
- 6ae - Monti DA, Mitchell E, Bazzan AJ, et al. Phase I Evaluation of Intravenous Ascorbic Acid in Combination with Gemcitabine and Erlotinib in Patients with Metastatic Pancreatic Cancer. *PLoS One.* 2012;7(1):e29794. doi:10.1371/journal.pone.0029794. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3260161/>
- 6af - <https://www.google.com/search?q=vitamin+C+1000mg+250+pills&tbm=shop> websearch for 1000mg tablets.
- 6ag - <http://hsionline.com/2003/05/28/vitamin-dosage-vs-vitamin-absorption/> , see Health Sciences Institute 05/2003
- 6ah - Benade L, Howard T, Burk D. Synergistic killing of Ehrlich ascites carcinoma cells by ascorbate and 3-amino-1,2,4,-triazole. *Oncology.* 1969;23(1):33-43. <https://www.ncbi.nlm.nih.gov/pubmed/5774953>

- 6ai - Casciari JJ, Riordan NH, Schmidt TL, et al. Cytotoxicity of ascorbate, lipoic acid, and other antioxidants in hollow fibre in vitro tumours. *Br J Cancer*. 2001;84(11):1544–1550. Doi:10.1054/bjoc.2001.1814. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363673>
- 6aj - Lamson DW, Gu YH, Plaza SM, et al. The vitamin C: vitamin K3 system - enhancers and inhibitors of the anticancer effect. *Altern Med Rev*. 2010;15(4):345-51. <https://www.ncbi.nlm.nih.gov/pubmed/21194250>
- 6ak - Verrax J, Taper H, Calderon BP. Targeting cancer cells by an oxidant-based therapy. *Curr Mol Pharmacol*. 2008;1(1):80-92. <https://www.ncbi.nlm.nih.gov/pubmed/20021426>
- 6al – Gupta C. CQ10 (coenzyme Q10) and Cancer. 2003. http://www.newmediaexplorer.org/chris/2003/07/31/cq10_coenzyme_q10_and_cancer.htm
- 6am - Tomasetti M, Straffella E, Staffolani S, et al. alpha-Tocopheryl succinate promotes selective cell death induced by vitamin K3 in combination with ascorbate. *Br J Cancer*. 2010;102(8):1224-34. doi:10.1038/sj.bjc.6605617. <https://www.ncbi.nlm.nih.gov/pubmed/20332775>
- 6an - https://docs.google.com/document/d/16iD0mHoSSTgGTedjRP-XQi3lI_b63eoBzOaaH3lI6gqQ/edit?usp=sharing
- 6ao - Pancorbo D, Vazquez C, Fletcher MA. Vitamin C-lipid metabolites: uptake and retention and effect on plasma C-reactive protein and oxidized LDL levels in healthy volunteers. *Med Sci Monit*. 2008;14(11):CR547-51. <http://www.ncbi.nlm.nih.gov/pubmed/18971870>
- 6ap - Efferth T. Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells. *Curr Drug Targets*. 2006;7(4):407-21. <http://www.ncbi.nlm.nih.gov/pubmed/16611029>
- 6aq – Yaletown Naturopathic Clinic. How does Artesunate kill cancer?. 2014. <http://yaletownnaturopathic.com/how-does-artesunate-kill-cancer/>
- 6ar - Alexander B, Fishman AI, Eshghi M. et al. Induction of cell death in renal cell carcinoma with combination of D-fraction and vitamin C. *Integr Cancer Ther*. 2013;12(5):442-8. doi:10.1177/1534735412473643. <https://www.ncbi.nlm.nih.gov/pubmed/23341484>
- 6as – Khan A, Marier D, Marsden E, et al. A Novel Form of Dichloroacetate Therapy for Patients With Advanced Cancer: A Report of 3 Cases. *Altern Ther Health Med*. 2014;20(2):21-28. http://alternative-therapies.com/at/web_pdfs/s202khan.pdf
- 6at - Sinnberg T, Noor S, Venturelli S, et al. The ROS-induced cytotoxicity of ascorbate is attenuated by hypoxia and HIF-1alpha in the NCI60 cancer cell lines. *J Cell Mol Med*. 2014;18(3):530–541. doi:10.1111/jcmm.12207. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955158/>
- 6au - <http://www.cancerfoundationforlife.org>
- 6av - Raghavendra RM, Nagarathna R, Nagendra HR, et al. Effects of an integrated yoga programme on chemotherapy-induced nausea and emesis in breast cancer patients. *Eur J Cancer Care (Engl)*. 2007;16(6):462-74. <http://www.ncbi.nlm.nih.gov/pubmed/17944760>
- 6aw - http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/e19527
- 6ax - <http://www.consultant360.com/article/role-exercise-patients-cancer>
- 6ay - Cascinu S, Catalano V, Cordella L, et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. *J Clin Oncol*. 2002;20(16):3478-83. <https://www.ncbi.nlm.nih.gov/pubmed/12177109>
- 6az - Böhm S, Oriana S, Spatti G, et al. Dose intensification of platinum compounds with glutathione protection as induction chemotherapy for advanced ovarian carcinoma. *Oncology*. 1999;57(2):115-20. <https://www.ncbi.nlm.nih.gov/pubmed/10461057>
- 6ba - <http://curezone.org/forums/fm.asp?i=1909163>
- 6bb - Raffaghello L, Lee C, Safdie FM, et al. Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. *Proc Natl Acad Sci U S A*. 2008;105(24):8215-20. doi:10.1073/pnas.0708100105. <http://www.ncbi.nlm.nih.gov/pubmed/18378900>
- 6bc - Krone CA, Ely JT. Controlling hyperglycemia as an adjunct to cancer therapy. *Integr Cancer Ther*. 2005;4(1):25-31. <http://www.ncbi.nlm.nih.gov/pubmed/15695475>

- 6bd - Santisteban GA, Ely JT, Hamel EE, et al. Glycemic modulation of tumor tolerance in a mouse model of breast cancer. *Biochem Biophys Res Commun*. 1985;132(3):1174-9. <https://www.ncbi.nlm.nih.gov/pubmed/4074351>
- 6be - Mojić M, Pristov JB, Maksimović-Ivanić D, et al. Extracellular iron diminishes anticancer effects of vitamin C: An in vitro study. *Sci Rep*. 2014;4:5955. doi:10.1038/srep05955. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4121606/>
- 6bf - Hempel SL, Buettner GR, Wessels DA, et al. Extracellular iron (II) can protect cells from hydrogen peroxide. *Arch Biochem Biophys*. 1996;330(2):401-8. <http://www.ncbi.nlm.nih.gov/pubmed/8660671>
- 6bg - <http://www.vitaminfoundation.org>, forum search owen hydrocortisone ivc
- 6bh - [^] Mukherjee, Siddhartha. "The Cancer Sleeper Cell". *New York Times*. New York Times. Retrieved 15 July 2014.
- 6bi – Lisanti MP, Sotgia F. Vitamin C and Doxycycline: A synthetic lethal combination therapy targeting metabolic flexibility in cancer stem cells (CSCs). *Oncotarget*. 2017;8:67269-67286. <http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=18428&path%5B%5D=59195>
- 6bj - Tomasetti M, Nocchi L, Neuzil J, et al. Alpha-Tocopheryl Succinate Inhibits Autophagic Survival of Prostate Cancer Cells Induced by Vitamin K3 and Ascorbate to Trigger Cell Death. *PLoS One*. 2012;7(12):e52263. doi:10.1371/journal.pone.0052263. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525640/> 6bk - The Journal of Orthomolecular Medicine, 5(3):143-154, 1990.
- 6bm - Santisteban GA, Ely JT, Hamel EE, et al. Glycemic modulation of tumor tolerance in a mouse model of breast cancer. *Biochem Biophys Res Commun*. 1985;132(3):1174-9. <http://www.ncbi.nlm.nih.gov/pubmed/4074351>
- 6bn - Krone CA, Ely JT. Controlling hyperglycemia as an adjunct to cancer therapy. *Integr Cancer Ther*. 2005;4(1):25-31. <http://www.ncbi.nlm.nih.gov/pubmed/15695475> 6bo - http://profiles.nlm.nih.gov/MM/B/B/R/R/_/mmbrr.pdf
- 6bp - Hoffer LJ, Levine M, Assouline S, et al. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. *Annals of Oncology* . 2008;19(11):1969–1974. <https://academic.oup.com/annonc/article/19/11/1969/199216/Phase-I-clinical-trial-of-i-v-ascorbic-acid-in> and Hoffer LJ, Levine M, Assouline S, et al. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. *Ann Oncol*. 2008;19(11):1969-74. Doi:10.1093/annonc/mdn377. <http://www.ncbi.nlm.nih.gov/pubmed/18544557>
- 6bq - Dawson ER, Morley SE, Robertson AG, et al. Increasing dietary supervision can reduce weight loss in oral cancer patients. *Nutr Cancer*. 2001;41(1-2):70-4. <http://www.ncbi.nlm.nih.gov/pubmed/12094631>
- 6br - [Chemo effect on IVC patients - Pauling http://profiles.nlm.nih.gov/MM/B/B/R/R/_/mmbrr.pdf](http://profiles.nlm.nih.gov/MM/B/B/R/R/_/mmbrr.pdf)
- 6bs - Mojić M, Pristov JB, Maksimović-Ivanić D. Extracellular iron diminishes anticancer effects of vitamin C: An in vitro study. *Sci Rep*. 2014;4:5955. doi:10.1038/srep05955. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4121606/>
- 6bt - <http://books.google.com/books?id=bNmluHxe4g0C>
- 6bu - Lamson DW, Gu YH, Plaza SM, et al. The vitamin C: vitamin K3 system - enhancers and inhibitors of the anticancer effect. *Altern Med Rev*. 2010;15(4):345-51. <http://www.ncbi.nlm.nih.gov/pubmed/21194250>
- 6bv - Lee JH, Kim GH. Evaluation of antioxidant and inhibitory activities for different subclasses flavonoids on enzymes for rheumatoid arthritis. *J Food Sci*. 2010;75(7):H212-7. doi: 10.1111/j. <https://www.ncbi.nlm.nih.gov/pubmed/21535545>
- 6bw - Torti SV, Torti FM. Iron and cancer: more ore to be mined. *Nat Rev Cancer*. 2013;13(5):342–355. doi:10.1038/nrc3495. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4036554/>

6bx - Wang F, Jiao P, Qi M, et al. Turning Tumor-Promoting Copper into an Anti-Cancer Weapon via

High-Throughput Chemistry. *Curr Med Chem*. 2010;17(25):2685–2698.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3786439/>

6ca - Shearer MJ, Newman P. Metabolism and cell biology of vitamin K. *Thromb Haemost*. 2008;100(4):530-47.

<https://www.ncbi.nlm.nih.gov/pubmed/18841274>

6cb - Miura K, Tai A. 2-O- α -D-Glucopyranosyl-L-ascorbic acid as an antitumor agent for infusion therapy. *Biochem Biophys Res Commun*. 2017;10:232–236. doi: 10.1016/j.bbrep.2017.04.014 .

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5614674/>

6cc - [The Riordan Intravenous Vitamin C \(IVC\) Protocol For Adjunctive Cancer Care: IVC as a Chemotherapeutic and Biological Response Modifying Agent](#)

Hugh Riordan, MD,

Neil Riordan, PhD, Joseph Casciari, PhD, James Jackson, PhD,
Ron Hunninghake, MD, Nina Mikirova, PhD, and Paul R. Taylor

6cd - University of Kansas Medical Center, KU Integrative Medicine, [GENERAL ONCOLOGY PROTOCOL](#) updated 4/11/2014

6ce - Tovmasyan A, Sampaio RS, Boss MK, et al. Anticancer therapeutic potential of Mn porphyrin/ascorbate system. *Free Radic Biol Med*. 2015;89:1231-47. doi: 10.1016/j. <https://www.ncbi.nlm.nih.gov/pubmed/26496207>

6cf - Younghoon Jeon, Jun Seok Park, Suyoung Moon, and Jinseok Yeo; Effect of Intravenous High Dose Vitamin C on Postoperative Pain and Morphine Use after

Laparoscopic Colectomy: A Randomized Controlled Trial. *Pain Res Manag*. 2016;2016:9147279. Epub 2016 Oct 30.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5107231/>

6cg - Sadeghpour A, Alizadehasl A, Kyavar M, et al.; Impact of Vitamin C Supplementation on Post-Cardiac Surgery ICU and Hospital Length of Stay. *Anesth Pain Med*.

2015;5(1):e25337. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4350190/>

6ch - MacKay D1, Miller AL. Nutritional support for wound healing. *Altern Med Rev*. 2003 Nov;8(4):359-77.

<https://www.ncbi.nlm.nih.gov/pubmed/14653765>

6ci - Long CL, Maull KI, Krishnan RS, Laws HL, Geiger JW, Borghesi L, Franks W, Lawson TC, Sauberlich HE. Ascorbic acid dynamics in the seriously ill and injured. *J Surg Res*. 2003 Feb;109(2):144-8.

<https://www.ncbi.nlm.nih.gov/pubmed/12643856>

6cj - JJamdar J, Rao B, Netke S, Roomi MW, Ivanov V, Niedzwiecki A, Rath M. Reduction in tibial shaft fracture healing time with essential nutrient supplementation containing ascorbic acid, lysine, and proline. *Altern Complement Med*. 2004 Dec;10(6):915-6. <https://www.ncbi.nlm.nih.gov/pubmed/15729747>

6ck - Ayatollahi V, Dehghanpour Farashah S, Behdad S, Vaziribozorg S, Rabbani Anari M; Effect of intravenous vitamin C on postoperative pain in uvulopalatopharyngoplasty with tonsillectomy. *Clin Otolaryngol*. 2017

Feb;42(1):139-143. doi: 10.1111/coa.12684. Epub 2016 Jun 7. <https://www.ncbi.nlm.nih.gov/pubmed/27219124>

6cl - Orlando A, Linsalata M, Tutino V, D'Attoma B, Notarnicola M, Russo F. Vitamin K1 exerts antiproliferative effects and induces apoptosis in three differently graded human colon cancer cell lines. *Biomed Res Int*. 2015;2015:296721.

Epub 2015 May 17. <https://www.ncbi.nlm.nih.gov/pubmed/26075224>

6cm - Duan F1, Yu Y2, Guan R2, Xu Z1, Liang H2, Hong L1. Vitamin K2 Induces Mitochondria-Related Apoptosis in Human Bladder Cancer Cells via ROS and JNK/p38 MAPK Signal Pathways. *PLoS One*. 2016 Aug

29;11(8):e0161886. doi: 10.1371/journal.pone.0161886. <https://www.ncbi.nlm.nih.gov/pubmed/27570977>

6cn - Mizuta T, Ozaki I. [Hepatocellular carcinoma and vitamin K2]. *Clin Calcium*. 2015 Nov;25(11):1645-51. doi: CliCa151116451651. <https://www.ncbi.nlm.nih.gov/pubmed/26503869>

6co - Nelson Ho, Jodi Morrison, Andreza Silva, and Brenda L. Coomber. The effect of 3-bromopyruvate on human colorectal cancer cells is dependent on glucose concentration but not hexokinase II expression. *Biosci Rep*. 2016

Feb; 36(1): e00299. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4759612/>

7a - *The Journal of Orthomolecular Medicine*, 5(3):143-154, 1990

7b - Ranzato E, Biffo S, Burlando B. Selective ascorbate toxicity in malignant mesothelioma: a redox Trojan mechanism. *Am J Respir Cell Mol Biol*. 2011;44(1):108-17. doi:

- 10.1165/rcmb.2009-0340OC. <https://www.ncbi.nlm.nih.gov/pubmed/20203294>
- 7c – Hickey S, Hillary J, Miller RJ. Pharmacokinetics of oral vitamin C. *Journal of Nutritional & Environmental Medicine*. 2009;17(3):169-177. <http://www.tandfonline.com/doi/abs/10.1080/13590840802305423>
- 7d – Hickey S, Roberts H. Vitamin C and Cancer: Is There A Use For Oral Vitamin C?. *JOM*. 2013;28(1):33-44. <https://www.isom.ca/wp-content/uploads/2017/04/Vitamin-C-and-Cancer-Is-There-A-Use-For-Oral-Vitamin-C-28.1.pdf>
- 7e - Padayatty SJ, Riordan HD, Hewitt SM, et al. Intravenously administered vitamin C as cancer therapy: three cases. *CMAJ*. 2006; 174(7): 937–942. doi:10.1503/cmaj.050346. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1405876>
- 7f - Cathcart RF. Vitamin C, titrating to bowel tolerance, anascorbemia, and acute induced scurvy. *Med Hypotheses*. 1981 Nov;7(11):1359-76 <https://www.ncbi.nlm.nih.gov/pubmed/7321921>
- 7g- Daniel U. Owu, Agona O. Obembe, Chukwuemeka R. Nwokocha, Ime E. Edoho, and Eme E. Osim. Gastric Ulceration in Diabetes Mellitus: Protective Role of Vitamin C. *ISRN Gastroenterol*. 2012: 362805. doi: 10.5402/2012/362805 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3384905/>
- 7h -Anupam Aditi, M.D. and David Y. Graham, M.D.. Vitamin C, Gastritis, and Gastric Disease: a historical review and update. *Dig Dis Sci*. 2012 Oct; 57(10). doi: 10.1007/s10620-012-2203-7 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3874117/>
- 7i - Nishikawa Y, Minenaka Y, Ichimura M, Tatsumi K, Nadamoto T, Urabe K. Effects of astaxanthin and vitamin C on the prevention of gastric ulcerations in stressed rats. *J Nutr Sci Vitaminol (Tokyo)*. 2005 Jun;51(3):135-41. <https://www.ncbi.nlm.nih.gov/pubmed/16161762>
- 7j - Brzozowski T, Kwiecień S, Konturek PC, Konturek SJ, Mitis-Musiol M, Duda A, Bielański W, Hahn EG. Comparison of nitric oxide-releasing NSAID and vitamin C with classic NSAID in healing of chronic gastric ulcers; involvement of reactive oxygen species. *Med Sci Monit*. 2001 Jul-Aug;7(4):592-9. <https://www.ncbi.nlm.nih.gov/pubmed/11433182>
- 7k - Chen-Road Hung and Su-Lin Neu. Acid-Induced Gastric Damage in Rats Is Aggravated by Starvation and Prevented by Several Nutrients. *J. Nutr.* April 1, 1997 vol. 127 no. 4 630-636. <http://jn.nutrition.org/content/127/4/630.long>
- 7l - Jainu M, Mohan KV. Protective role of ascorbic acid isolated from *Cissus quadrangularis* on NSAID induced toxicity through immunomodulating response and growth factors expression. *Int Immunopharmacol*. 2008 Dec 20;8(13-14):1721-7. doi: 10.1016 <https://www.ncbi.nlm.nih.gov/pubmed/18773975>
- 7m - Koc M1, Imik H, Odabasoglu F. Gastroprotective and anti-oxidative properties of ascorbic acid on indomethacin-induced gastric injuries in rats. *Biol Trace Elem Res*. 2008 Winter;126(1-3):222-36. doi: 10.1007. <https://www.ncbi.nlm.nih.gov/pubmed/18726076>
- 8a - Ichim TE, Minev B, Braciak T, et al. Intravenous ascorbic acid to prevent and treat cancer-associated sepsis?. *JTM*. 2011. <http://www.translational-medicine.com/content/9/1/25/table/T1>
- 8b - Gonzalez MJ, Massari JRM, Duconge J, et al. Schedule Dependence in Cancer Therapy: Intravenous Vitamin C and the Systemic Saturation Hypothesis. *J Orthomol Med*. 2012;27(1):9–12. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4031610/>
- 8c - <http://infusionscientific.com>
- 8d - Uetaki M, Tabata S, Nakasuka F, et al. Metabolomic alterations in human cancer cells by vitamin C-induced oxidative stress. *Sci Rep*. 2015;5:13896. doi:10.1038/srep13896. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4563566/>
- 8e – Cameron E, Campbell A. THE ORTHOMOLECULAR TREATMENT OF CANCER* II. CLINICAL TRIAL OF HIGH-DOSE ASCORBIC ACID SUPPLEMENTS IN ADVANCED HUMAN CANCER. *Dept. of Clin. Res*. 1974. http://www4.dr-rath-foundation.org/NHC/studien_pdf/old/the_orthomolecular_treatment_of_cancer.pdf
- 8f - Vitamin C and Cancer: A Personal Perspective by Ewan Cameron. September 29-30, 1984. <http://scarc.library.oregonstate.edu/coll/cameron/cameron-personal/page1.html>
- 8g - Patel V, Fisher M, Voelker M, et al. Gastrointestinal effects of the addition of ascorbic acid to aspirin. *Pain Pract*. 2012;12(6):476-84. doi:10.1111/j.1533-2500.2011.00517.x. <http://www.ncbi.nlm.nih.gov/pubmed/22151399>

- 8h - Mojić M, Pristov JB, Maksimović-Ivanić D, et al. Extracellular iron diminishes anticancer effects of vitamin C: An in vitro study. *Sci Rep* . 2014;4:5955. doi: 10.1038/srep05955 .
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4121606/>__
- 8i - Hempel SL, Buettner GR, Wessels DA, et al. Extracellular iron (II) can protect cells from hydrogen peroxide. *Arch Biochem Biophys*. 1996;330(2):401-8. <http://www.ncbi.nlm.nih.gov/pubmed/8660671>
- 8j - Pham AN, Xing G, Miller CJ, et al. Fenton-like copper redox chemistry revisited: Hydrogen peroxide and superoxide mediation of copper-catalyzed oxidant production. *JoC*. 2013;301:54-64.
<http://www.sciencedirect.com/science/article/pii/S0021951713000377>__ 8k -
<http://www.ncbi.nlm.nih.gov/pubmed/?term=sodium+salicylate+cancer>__
- 8l - DENSON KW, BOWERS EF. The determination of ascorbic acid in white blood cells. A comparison of W.B.C. ascorbic acid and phenolic acid excretion in elderly patients. *Clin Sci*. 1961;21:157-62. <http://www.ncbi.nlm.nih.gov/pubmed/13885487>__
- 8m - Daş N, Nebioğlu S. Vitamin C aspirin interactions in laboratory animals. *J Clin Pharm Ther*. 1992;17(6):343-6.
<http://www.ncbi.nlm.nih.gov/pubmed/1287025>
- 8n - Johansson U, Akesson B. Interaction between ascorbic acid and acetylsalicylic acid and their effects on nutritional status in man. *Int J Vitam Nutr Res*. 1985;55(2):197-204. <http://www.ncbi.nlm.nih.gov/pubmed/4040504>
- 8o - Lammers T, Peschke P, Kühnlein R, et al. Effect of Intratumoral Injection on the Biodistribution and the Therapeutic Potential of HPMA Copolymer-Based Drug Delivery Systems. *Neoplasia*. 2006;8(10):788–795. doi:10.1593/neo.06436. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1715923/>__
- 8p - Wang G, Yin T, Wang Y. In vitro and in vivo assessment of high-dose vitamin C against murine tumors. *Exp Ther Med*. 2016;12(5):3058-3062. <https://www.ncbi.nlm.nih.gov/pubmed/27882116>
- 8q - Du J, Martin SM, Levine M, et al. MECHANISMS OF ASCORBATE-INDUCED CYTOTOXICITY IN PANCREATIC CANCER. *Clin Cancer Res*. 2010;16(2):509–520.
doi:10.1158/1078-0432.CCR-09-1713. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2807999/>__
- 8r – Leveen HH, Leveen RF, Leveen EG. Treatment of cancer with phlorizin and its derivatives. 1989.
<https://www.google.com/patents/US4840939>__
- 8s - *Proc Natl Acad Sci U S A*. 2015 Jul 28; 112(30): E4111–E4119.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522748/figure/fig06/>__
- 8t - Dönmez Y, Akhmetova L, İşeri ÖD, et al. Effect of MDR modulators verapamil and promethazine on gene expression levels of MDR1 and MRP1 in doxorubicin-resistant MCF-7 cells. *Cancer Chemother Pharmacol*. 2011;67(4):823-8. doi:10.1007/s00280-010-1385-y. <https://www.ncbi.nlm.nih.gov/pubmed/20563580>
- 8u - Louters LL, Stehouwer N, Rekman J, et al. Verapamil inhibits the glucose transport activity of GLUT1. *J Med Toxicol*. 2010;6(2):100-5. doi:10.1007/s13181-010-0072-z. <https://www.ncbi.nlm.nih.gov/pubmed/20354917>
- 8v – Gao JL, Chen YG. Natural Compounds Regulate Glycolysis in Hypoxic Tumor Microenvironment. *BioMed Research International*. 2015;2015:354143. <http://www.hindawi.com/journals/bmri/raa/354143/>
- 8w - Torres MP, Rachagani S, Purohit V, et al. Graviola: A Novel Promising Natural-Derived Drug That Inhibits Tumorigenicity and Metastasis of Pancreatic Cancer Cells In Vitro and In Vivo Through Altering Cell Metabolism. *Cancer Lett*. 2012;323(1):29–40. doi:10.1016/j.canlet.2012.03.031.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3371140/>__
- 8x - Bonuccelli G, Francesco EMD, Boer RD, et al. NADH autofluorescence, a new metabolic biomarker for cancer stem cells: Identification of Vitamin C and CAPE as natural products targeting “stemness”. *Oncotarget* . 2017 Mar 28; 8(13): 20667–20678. doi:10.18632/oncotarget.15400. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400535/>__
- 8y - Schmalhausen EV, Pleten' AP, Muronetz VI. Ascorbate-induced oxidation of glyceraldehyde-3-phosphate dehydrogenase. *Biochem Biophys Res Commun*. 2003 Aug 29;308(3):492-6.
<https://www.ncbi.nlm.nih.gov/pubmed/12914777>

8z - Chen Q, Espey MG, Krishna MC, et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues.

Proc Natl Acad Sci U S A. 2005;102(38):13604-9. <https://www.ncbi.nlm.nih.gov/pubmed/16157892>

8ab – Chen Q, Espey MG, Krishna MC, et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissues. PNAS. 2005;102(38):13604-13609. doi:

10.1073/pnas.0506390102 <http://www.pnas.org/content/102/38/13604.long>

8ac - Lee EJ, Park HG, Kang HS. Sodium salicylate induces apoptosis in HCT116 colorectal cancer cells through activation of p38MAPK. Int J Oncol. 2003;23(2):503-8. <https://www.ncbi.nlm.nih.gov/pubmed/12851702>

8ad - Kim HW, Cho SI, Bae S, et al. Vitamin C Up-regulates Expression of CD80, CD86 and MHC Class II on Dendritic Cell Line, DC-1 Via the Activation of p38 MAPK. Immune Netw. 2012; 12(6):277–283.

doi:10.4110/in.2012.12.6.277. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3566423/>